{"id":"fosmidomycin-and-clindamycin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fosmidomycin targets the 1-deoxy-D-xylulose-5-phosphate reductoisomerase enzyme, which is crucial for the production of isoprenoids. This leads to a reduction in the levels of isoprenoids, which are essential for the growth and survival of certain bacteria. Clindamycin, on the other hand, binds to the 50S ribosomal subunit, preventing the elongation of the peptide chain and ultimately inhibiting protein synthesis.","oneSentence":"Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase, which is involved in the biosynthesis of isoprenoids, while clindamycin is a lincosamide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:52.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of malaria caused by Plasmodium falciparum"},{"name":"Treatment of bacterial infections, including those caused by Staphylococcus aureus and Streptococcus pyogenes"}]},"trialDetails":[{"nctId":"NCT01464138","phase":"PHASE2","title":"Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children","status":"COMPLETED","sponsor":"Jomaa Pharma GmbH","startDate":"2010-09","conditions":"Malaria","enrollment":52},{"nctId":"NCT01002183","phase":"PHASE2","title":"Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate","status":"WITHDRAWN","sponsor":"Jomaa Pharma GmbH","startDate":"","conditions":"Malaria","enrollment":40},{"nctId":"NCT01361269","phase":"PHASE2","title":"Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria","status":"UNKNOWN","sponsor":"Zentopharm GmbH","startDate":"2011-06","conditions":"Malaria","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fosmidomycin and clindamycin","genericName":"Fosmidomycin and clindamycin","companyName":"Zentopharm GmbH","companyId":"zentopharm-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosmidomycin and clindamycin are being studied in clinical trials for the treatment of acute uncomplicated Plasmodium falciparum malaria. Fosmidomycin and clindamycin are co-administered in a multicentre evaluation for this condition.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}